$10.69
+0.61 (+6.05%)
Open$10.36
Previous Close$10.08
Day High$11.46
Day Low$10.00
52W High$14.93
52W Low$4.60
Volume—
Avg Volume118.2K
Market Cap199.05M
P/E Ratio—
EPS$-2.62
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+199.7% upside
Current
$10.69
$10.69
Target
$32.04
$32.04
$22.50
$32.04 avg
$35.39
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 32.29M | 31.67M | 27.66M |
| Net Income | 4.35M | 5.71M | 3.74M |
| Profit Margin | 13.5% | 18.0% | 13.5% |
| EBITDA | 8.33M | 8.25M | 7.51M |
| Free Cash Flow | 3.02M | 4.79M | 4.27M |
| Rev Growth | +12.6% | +22.6% | -0.7% |
| Debt/Equity | 0.19 | 0.18 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |